A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)

Antonio Viúdez; Filipe L.F. Carvalho; Zahra Maleki; Marianna Zahurak; Daniel Laheru; Alejandro Stark; Nilofer Z. Azad; Christopher L. Wolfgang; Stephen Baylin; James G. Herman; Ana De Jesus-Acosta

doi:10.18632/oncotarget.7436

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers: Pathology:

This article has been corrected. Correction in: Oncotarget. 2017; 8(11):18617.

A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)

Antonio Viúdez, Filipe L.F. Carvalho, Zahra Maleki, Marianna Zahurak, Daniel Laheru, Alejandro Stark, Nilofer Z. Azad, Christopher L. Wolfgang, Stephen Baylin, James G. Herman and Ana De Jesus-Acosta _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:24950-24961. https://doi.org/10.18632/oncotarget.7436

Metrics: PDF 1782 views | HTML 2517 views | ?

Abstract

Antonio Viúdez1,2, Filipe L.F. Carvalho1, Zahra Maleki3, Marianna Zahurak4, Daniel Laheru1, Alejandro Stark1, Nilofer Z. Azad1, Christopher L. Wolfgang1, Stephen Baylin1, James G. Herman1, Ana De Jesus-Acosta1

1Department of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medical Institutions, Baltimore, Maryland, USA

2Department of Medical Oncology, Complejo Hospitalario de Navarra-Instituto de Investigaciones Sanitarias de Navarra-IDISNA, Pamplona, Navarra, Spain

3Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA

4The Division of Biostatistics and Bioinformatics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Correspondence to:

Antonio Viúdez, e-mail: [email protected], [email protected]

Keywords: pancreatic neuroendocrine tumor, MGMT, NDRG-1, PHLDA-3, immunohistochemistry, Pathology Section

Received: October 01, 2015 Accepted: January 23, 2016 Published: February 17, 2016

ABSTRACT

Pancreatic neuroendocrine tumor (PanNET) is a neoplastic entity in which few prognostic factors are well-known. Here, we aimed to evaluate the prognostic significance of N-myc downstream-regulated gen-1 (NDRG-1), O6-methylguanine DNA methyltransferase (MGMT) and Pleckstrin homology-like domain family A member 3 (PHLDA-3) by immunohistochemistry (IHC) and methylation analysis in 92 patients with resected PanNET and follow-up longer than 24 months. In multivariate analyses, ki-67 and our immunohistochemistry prognostic score (IPS-based on MGMT, NDRG-1 and PHLDA-3 IHC expression) were independent prognostic factors for disease-free-survival (DFS), while age and IPS were independent prognostic factors for overall survival (OS). Our IPS could be a useful prognostic biomarker for recurrence and survival in patients following resection for PanNET.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7436

Publication Alerts

Research Papers: Pathology:

A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)

Abstract